secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001628280-23-037893
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI reports Q3 revenue $82M (+26% YoY), net loss widens to $17.4M from $2.7M
----------------------------------------------------------------------------

- Revenue $82M (+26% YoY); gross profit $16M (+23% YoY); gross margin 19.5% (down from 20.0%).
- Net loss $17.4M ($0.19 diluted loss) vs $2.7M loss ($0.03 loss) prior year; Adjusted EBITDA loss $(5.3)M vs $(6.7)M.
- Cash and investments $87.4M as of Sept 30, 2023.
- Opened 70th clinic, added 5 physicians (total 112); signed full-risk capitated contract in South Florida effective Jan 1, 2024.
- Reaffirmed full year 2023 guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000162828023037893/0001628280-23-037893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000162828023037893/toi-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer